Patents Assigned to FLONEXT S.R.L.
  • ANTISENSE OLIGONUCLEOTIDE FOR USE IN THE TREATMENT OF PSORIASIS-INDUCED ITCHING AND PHOSPHOLIPID VESICLE COMPRISING SAID OLIGONUCLEOTIDE
    Publication number: 20250043280
    Abstract: The present invention relates to the use of an oligonucleotide complementary to the sequence of human miR-203b-3p microRNA in the treatment of psoriasis-induced itching. The present invention concerns also a phospholipid vesicle comprising said oligonucleotide and the use of said phospholipid vesicle for the prevention and/or treatment of psoriasis-induced itching.
    Type: Application
    Filed: November 23, 2022
    Publication date: February 6, 2025
    Applicant: FLONEXT S.R.L.
    Inventors: Romina NASSINI, Pierangelo GEPPETTI, Francesco DE LOGU
  • TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES
    Publication number: 20240285623
    Abstract: The present invention relates to TRPA1 channel antagonist compounds for use in the prevention and/or treatment of retinal diseases, in particular in the prevention and/or treatment of macular degeneration. The present invention also relates to an ophthalmic composition comprising at least one TRPA1 channel antagonist compound for topical ophthalmic use in the prevention and/or treatment of at least one degenerative retinal disease, preferably macular degeneration.
    Type: Application
    Filed: June 7, 2022
    Publication date: August 29, 2024
    Applicant: FLONEXT S.R.L.
    Inventors: Pierangelo GEPPETTI, Romina NASSINI, Francesco DE LOGU
  • PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES
    Publication number: 20240269115
    Abstract: The present invention relates to compounds belonging to the pyrazolone class for use in the prevention and/or treatment of degenerative retinal diseases, in particular in the prevention and/or treatment of macular degeneration. The present invention also relates to a pharmaceutical composition comprising at least one compound belonging to the pyrazolone class, preferably a topical ophthalmic composition, for use in the prevention and/or treatment of degenerative retinal diseases, preferably macular degeneration.
    Type: Application
    Filed: June 7, 2022
    Publication date: August 15, 2024
    Applicant: FLONEXT S.R.L.
    Inventors: Pierangelo GEPPETTI, Romina NASSINI, Francesco DE LOGU